Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

391
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
391
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

356
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
356
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

993
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
993
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

947
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
947
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Select Contemporary Statistical Concepts in Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory.

JACC. Heart failure·2026
Same author

Rebuilding U.S. Heart Failure Site-Based Research: A National Expert Authority Blueprint From the Heart Failure Collaboratory.

JACC. Heart failure·2026
Same author

Forty Years of Heart Failure Drug Clinical Trials: Have We Made Progress on Enrollment?

JACC. Heart failure·2026
Same author

Aligning Coronary Stent Trial Enrollment With the U.S. Intended-Use Population: Implications of Site Selection.

Journal of the American College of Cardiology·2026
Same author

Association of the Timing of Acute Declines in Kidney Function in Acute Heart Failure With Cardiovascular and Kidney Outcomes.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Michael R. Bristow, MD, PhD: A Translational Pioneer Who Changed the Field of Heart Failure.

JACC. Basic to translational science·2026

Related Experiment Video

Updated: Feb 10, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Pharmacogenetics in heart failure trials.

Mona Fiuzat1, Michael R Bristow

  • 1Duke University Medical Center, 2400 Pratt Street, Durham, NC 27710, USA. mona.fiuzat@duke.edu

Heart Failure Clinics
|September 20, 2011
PubMed
Summary

Pharmacogenetics holds promise for personalizing heart failure treatment by predicting patient response. Further research is needed to overcome challenges and support clinical application for better outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacogenetics
  • Genomic Medicine

Background:

  • Heart failure (HF) presents significant mortality and morbidity.
  • Treatment response in HF patients is highly heterogeneous.
  • Predicting individual treatment response is crucial for optimizing care.

Purpose of the Study:

  • To explore the potential of pharmacogenetic targets in heart failure.
  • To address challenges and evidence requirements for pharmacogenetic applications in HF.
  • To highlight the need for predictable treatment responses in HF patients.

Main Methods:

  • Review of current research on pharmacogenetics in heart failure.
  • Analysis of challenges hindering clinical implementation.
  • Assessment of the existing evidence base for pharmacogenetic strategies.

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Experiment Videos

Last Updated: Feb 10, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Main Results:

  • Pharmacogenetic research in heart failure is ongoing.
  • Significant challenges impede the widespread adoption of pharmacogenetics in HF.
  • The need for predictable treatment responses is evident due to HF's heterogeneity.

Conclusions:

  • Pharmacogenetics offers potential for personalized heart failure therapy.
  • Further research is essential to strengthen the evidence and facilitate clinical integration.
  • While not yet standard, pharmacogenetic testing in heart failure is a foreseeable advancement.